CagriSema (Cagrilintide + Semaglutide)

Overview

CagriSema is the combination of the long-acting amylin analog Cagrilintide with the GLP-1 receptor agonist Semaglutide — two molecules acting through distinct receptor families (the amylin / calcitonin-receptor axis and the GLP-1 receptor) that the metabolic-research literature studies together under the CagriSema designation. As an investigational combination it is not an approved finished drug; the material referenced here is a research reagent only, framed as a reference pairing rather than for any weight-management outcome. Lyochem's methodology preference for a two-component system is to characterize each component on its own analytical packet rather than ship a pre-mixed blend whose per-component data is obscured. Cagrilintide and Semaglutide are each supplied as separately characterized lots — RP-HPLC purity (gradient method, UV 214 nm), ESI-MS identity, sequence confirmation by LC-MS/MS, counter-ion content, and water content by Karl Fischer per lot — so a lab can confirm identity and purity of each before preparing the combination in-protocol at its own ratio. Because the components carry individual CAS numbers rather than a single registered identifier for the combination, the per-lot COA is the operative identity document; confirm the API of each component by COA / label before use. Fills run mg-scale; this is reference-grade research material, distinct from compounding-scale API supply.

Applications & buyer fit

Specifications

CAS

(blend, components have individual CAS numbers)

Purity (HPLC)

≥ 99.0% (component-wise for blends)

Strength

5 mg – 20 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 1 week

MOQ

On request

Lead time

14–21 days

Storage

2–8°C, protect from light

Documentation available on request

• Lot-specific Certificate of Analysis (CoA)
• RP-HPLC chromatogram with peak integration
• ESI-MS identity confirmation (±0.5 Da)
• Sequence verification by LC-MS/MS
• Water content by Karl Fischer
• SDS / MSDS
• Counter-ion content (acetate / TFA)
• Peptide content (% net peptide)
• Bacterial endotoxin (LAL) on request — in vivo workflows

Regulatory note

Investigational combination; not approved as a finished drug at the time of writing. Components carry individual CAS numbers — confirm each component's API identity by batch COA / label before use. Sold for Research Use Only under the receiving laboratory's institutional and jurisdictional regulations — not a finished dosage form and not labelled for human administration. Buyers are responsible for institutional biosafety review and import-eligibility verification.

Selected literature

1. Garvey WT, Blüher M, Osorto Contreras CK, et al; REDEFINE 1 Study Group. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):635-647.
2. Davies MJ, Bajaj HS, Broholm C, et al; REDEFINE 2 Study Group. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):648-659.
3. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730.
4. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172.
5. Yamauchi T, Becker NP, Hagemann CA, et al; REDEFINE 5 study group. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2026;14(6):450-462.
6. Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study. Lancet Diabetes Endocrinol. 2026 Jun 7. [Epub ahead of print].

Frequently asked questions